An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Completed · Phase 1

Conditions studied: Alzheimer's Disease

In brief

This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and fasted conditions in healthy subjects.

Key facts

Study ID

NCT01716897

Run by

Eisai Inc.

People needed

18

Starts

2012-10-01

Expected to finish

2013-02-01

Last updated by the study team

2013-05-22

Who can join

Age: 30 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Caucasian males defined as persons of a European or Latin American descent
• Healthy male 30 to 55 years inclusive at the time of informed consent
• Body mass index (BMI) of 18 to 32 kg/m2 at Screening
• Subjects must have had a successful vasectomy (confirmed azoospermia), or they and their female partners must not be of childbearing potential or must be practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation. No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.

You may not qualify if…

• Any history of seizures or epilepsy (not including a history of simple febrile seizures in childhood) or disturbance of consciousness likely to be due to seizures
• Any medical condition which, in the opinion of the investigator has high risk of seizures (e.g., history of traumatic brain injury associated with loss of consciousness or amnesia, alcohol abuse, substance abuse) at Screening or within past 5 years
• Any history of cerebrovascular disease (stroke or transient ischemic attack)
• A history of prolonged QT/QTc interval or prolonged period from the beginning of the QRS complex to the end of the T wave on an ECG (QT)/ QT corrected for heart rate using Fridericia?s formula (QTcF) interval (QTcF \> 450 ms) as demonstrated by the mean of triplicate electrocardiogram (ECGs) (recorded at least 1 min apart) at Screening or Baseline Period
• Any other clinically significant ECG abnormalities at Screening or Baseline Periods, e.g. component of the ECG cycle from onset of atrial depolarization to onset of ventricular depolarization (PR)\>220 ms, component of ECG wave representing ventricular depolarization (QRS)\>110 ms
• Hypersensitivity to the study drugs or any of their excipients

Where it is running

• California Clinical Trials/Parexel — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.